Health Care sector company Merck & Company posted a -2.48% performance today, while the S&P 500 returned 0.04%.
24 analysts are following Merck & Company and have set target prices ranging from $96.0 to $135.0 per share. On average, they have given the company a rating of buy. At today's prices, MRK is trading -8.75% away from its average analyst target price of $118.92 per share.
Over the last year, MRK's share price has increased by 49.21%, which represents a difference of 56.02% when compared to the S&P 500. The stock's 52 week high is $115.49 per share whereas its 52 week low is $74.92. With an average free cash flow of $22,004,600,000.0 that have been growing at an average rate of 109.97% over the last four years, Merck & Company is in a position to continue its strong stock performance trend.
| Date Reported | Cash Flow from Operations (k) | Capital Expenditures (k) | Free Cash Flow (k) | YoY Growth |
|---|---|---|---|---|
| 2022-12-31 | $52,888,000 | $4,388,000 | $48,500,000 | 29.95% |
| 2021-12-31 | $41,769,000 | $4,448,000 | $37,321,000 | 540.81% |
| 2020-12-31 | $10,253,000 | $4,429,000 | $5,824,000 | -42.17% |
| 2019-12-31 | $13,440,000 | $3,369,000 | $10,071,000 | 21.24% |
| 2018-12-31 | $10,922,000 | $2,615,000 | $8,307,000 | n/a |
